


PHARMACEUTICAL 2020

Lexaria Bioscience Corp. Rank 338 of 362







PHARMACEUTICAL 2020

Lexaria Bioscience Corp. Rank 338 of 362



The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 215% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Other Expenses, reducing the Economic Capital Ratio by 901% points.

The company's Economic Capital Ratio, given in the ranking table, is -989%, being 686% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,819
Cost of Goods Sold	23
Intangible Assets	0
Liabilities, Current	185
Liabilities, Non-Current	0
Other Assets	265
Other Compr. Net Income	0
Other Expenses	3,505
Other Liabilities	0
Other Net Income	0
Property and Equipment	591
Research and Development	556
Revenues	223
Selling, General and Administrative Expense	297

Output Variable	Value in 1000 USD
Assets	2,675
Liabilities	185
Expenses	4,381
Stockholders Equity	2,491
Net Income	-4,158
Comprehensive Net Income	-4,158
Economic Capital Ratio	-989%